Spruce Biosciences

SPRB Rare disease Lead: Preclinical 4 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-09

Catalyst timeline

TA-ERT tralesinidase alfa BLA filing4Q 2026TA-ERT tralesinidase alfa BLA filing, 4Q 2026, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

tralesinidase alfa

TA-ERT

Protein Target: NAGLU, rhNAGLU

Mucopolysaccharidosis Type IIIB intracerebroventricular NCT07579910

SPR202

Protein Target: CRF, CRH

Congenital Adrenal Hyperplasia Preclinical HBM Alpha Therapeutics

Discontinued (1)

tildacerfont — Major Depressive Disorder · serious adverse event — significant elevation of liver enzymes in a patient

Biotech Distilled coverage (4)

2026-08-24 UPDATE: Spruce Biosciences (SPRB) - The Factory Signed Off 🔒 Paid
2026-08-13 UPDATE: Spruce Biosciences (SPRB) - The Patients Just Bought the Stock 🔒 Paid
2026-07-28 UPDATE: Spruce Biosciences (SPRB) - They Hired the Man Who Launched Brineura
2026-05-08 Spruce Biosciences (SPRB) - Scientific Deep Dive for Tralesinidase and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.